Stock Analysis
EQL Pharma (NGM:EQL) Full Year 2024 Results
Key Financial Results
- Revenue: kr264.2m (up 1.6% from FY 2023).
- Net income: kr22.7m (down 27% from FY 2023).
- Profit margin: 8.6% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: kr0.78 (down from kr1.06 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
EQL Pharma Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 47%.
Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare industry in Sweden.
Performance of the Swedish Healthcare industry.
The company's shares are up 13% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for EQL Pharma that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether EQL Pharma is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:EQL
EQL Pharma
Engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe.
Exceptional growth potential with mediocre balance sheet.